Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases

Transforming the
Lives of Patients

WITH SEVERE GENETIC AND ORPHAN DISEASES

We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform READ MORE >>

spotlight

December 15, 2014

bluebird bio Announces Pricing of Public Offering of Common Stock

Read More

December 15, 2014

bluebird bio Announces Proposed Public Offering of Common Stock

Read More

December 8, 2014

bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free

Read More

November 12, 2014

bluebird bio Reports Fiscal Third Quarter 2014 Financial Results

Read More

November 10, 2014

James M. DeTore joins bluebird bio as Chief Financial Officer

Read More